ã»ã¯ã¿:
å¥åº·ç®¡ç
æ¥ç:
ãã€ãªãã¯ãããžãŒ
ã¢ã¯ã»ã¹ãååŸ
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã®æéãã©ã³ã§ã¯ãå¶éãªããµãŒãã¹ãå©çšã§ãããã¹ãŠã®æ
å ±ãå©çšå¯èœã«ãªããŸãã
ãã£ã³ã¬ã³ãžã®è©äŸ¡
ä»åŸã®ã€ãã³ã Silverback Therapeutics Inc
ãã¹ãŠã®ã€ãã³ã
ä»åŸã®ã€ãã³ãã¯äºå®ãããŠããŸãã
èŠçŽåæ Silverback Therapeutics Inc
ã¢ã¯ã»ã¹ãååŸ
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã£ã³ã¬ã³ãžæ ªã®æ Œä»ã
ãã®æéãã©ã³ã§ã¯ãå¶éãªããµãŒãã¹ãå©çšã§ãããã¹ãŠã®æ
å ±ãå©çšå¯èœã«ãªããŸãã
売äžé«ãšçŽå©ç Silverback Therapeutics Inc
ãã¹ãŠã®ãã©ã¡ãŒã¿
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
äœæ:
11682 El Camino Real, San Diego, CA, United States, 92130
äŒç€Ÿå:
Silverback Therapeutics Inc
çºè¡è
ãã£ãã«ãŒ:
SPRY
ISIN:
US82835W1080
åœ:
ã¢ã¡ãªã«åè¡åœ
亀æ:
NASDAQ
é貚:
$
äžå Žæ¥:
2020-12-04
ã»ã¯ã¿:
å¥åº·ç®¡ç
æ¥ç:
ãã€ãªãã¯ãããžãŒ
ãµã€ã:
https://ars-pharma.com
https://ars-pharma.com
